We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$908M
AUM Growth
+$52.9M
Cap. Flow
+$30.8M
Cap. Flow %
3.39%
Top 10 Hldgs %
29.34%
Holding
100
New
7
Increased
28
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
HBNC icon
Horizon Bancorp
HBNC
+$17.6M
2
HCA icon
HCA Healthcare
HCA
+$17.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.66M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.58M
5
LLY icon
Eli Lilly
LLY
+$7.22M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.8M
2
ARRY
Array Biopharma Inc
ARRY
+$14.8M
3
AGN
Allergan plc
AGN
+$13M
4
CI icon
Cigna
CI
+$9.95M
5
WBA
Walgreens Boots Alliance
WBA
+$9.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.04%
2 Financials 2.97%
3 Industrials 0.36%
4 Technology 0.08%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
51
DELISTED
Medicines Co
MDCO
$7.29M 0.8%
200,000
+70,000
+54% +$2.29M
RARX
52
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$6.89M 0.76%
229,000
+79,000
+53% +$1.81M
AMRN
53
Amarin Corp
AMRN
$303M
$6.8M 0.75%
17,540
-1,000
-5% -$366K
EPZM
54
DELISTED
Epizyme, Inc
EPZM
$6.2M 0.68%
493,679
+434,474
+734% +$5.59M
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.92M 0.65%
81,550
-10,000
-11% -$767K
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$750M
$5.91M 0.65%
226,494
– –
VRAY
57
DELISTED
ViewRay, Inc.
VRAY
$5.85M 0.64%
664,023
– –
EW icon
58
Edwards Lifesciences
EW
$51.7B
$5.83M 0.64%
94,755
+15,000
+19% +$907K
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$4.92M 0.54%
1,234,335
+949,335
+333% +$5.5M
DERM
60
DELISTED
Dermira, Inc.
DERM
$4.78M 0.53%
500,329
– –
SAGE
61
DELISTED
Sage Therapeutics
SAGE
$3.96M 0.44%
21,639
-30,000
-58% -$5.12M
MDGL icon
62
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.9M 0.43%
37,225
+10,000
+37% +$1.07M
NSTG
63
DELISTED
NanoString Technologies, Inc.
NSTG
$3.64M 0.4%
120,000
– –
HMSY
64
DELISTED
HMS Holdings Corp.
HMSY
$3.24M 0.36%
+100,000
New +$3.06M
AIMT
65
DELISTED
Aimmune Therapeutics
AIMT
$3.11M 0.34%
149,201
– –
ABEO icon
66
Abeona Therapeutics
ABEO
$413M
$3.1M 0.34%
25,965
– –
ICPT
67
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.99M 0.33%
+37,600
New +$3.37M
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$2.88M 0.32%
70,000
– –
ALKS icon
69
Alkermes
ALKS
$8.25B
$2.71M 0.3%
120,399
– –
RVNC
70
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.51M 0.28%
193,181
– –
QGEN icon
71
Qiagen
QGEN
$8.72B
$2.44M 0.27%
56,583
– –
VKTX icon
72
Viking Therapeutics
VKTX
$4B
$2.42M 0.27%
+291,499
New +$2.49M
ADVM
73
DELISTED
Adverum Biotechnologies
ADVM
$1.42M 0.16%
11,967
– –
PVLA
74
Palvella Therapeutics
PVLA
$2.27B
$1.41M 0.16%
3,750
– –
ONCE
75
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.02M 0.11%
+10,000
New +$1.08M
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rhenman & Partners Asset Management held 100 positions worth $908M, up 6.2% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $30.8M of net new capital in Q2 2019, opening 7 new positions and adding to 28 existing holdings. Its largest new stake was Horizon Bancorp: 1,087,656 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.95M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2019 buy was Horizon Bancorp: 1,087,656 shares worth $26.2M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $9.66M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2019 reduction was Cigna, cutting an estimated $9.95M.
  • Rhenman & Partners Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019, selling an estimated $24.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $908M portfolio in Q2 2019.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 12 in Q2 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 6.2% quarter-over-quarter to $908M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2019, filed 22 Jul 2019.